Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Caffeinated Gum Use and Volleyball Performance

15. maj 2026 opdateret af: Gülbin Rudarlı, Ege University

Acute Effects of Caffeinated Gum Use on Volleyball Performance: A Randomized, Placebo-Controlled Crossover Trial

This study examined the acute effects of caffeinated chewing gum on volleyball performance in trained female volleyball players. Caffeine is commonly used by athletes to improve performance, but less is known about whether caffeinated gum is useful during volleyball-specific activity.

Participants completed three testing sessions in a randomized crossover design. In one session, they chewed placebo gum. In another session, they chewed caffeinated gum containing a single 300 mg dose of caffeine. In the third session, they received the same total amount of caffeine as three separate 100 mg doses given at 30-minute intervals.

The study assessed volleyball-specific skill performance, including attack, block, and defense efficiency, during a volleyball-specific skill game. Vertical jump height, heart rate, perceived exertion, side effects, and condition guessing were also recorded.

Studieoversigt

Detaljeret beskrivelse

This randomized, placebo-controlled, crossover study investigated whether the pattern of caffeinated gum administration affects volleyball-specific performance in trained female volleyball players. Participants completed one familiarization session and three experimental sessions separated by one week. The experimental conditions were placebo gum, single-dose caffeinated gum, and partial-dose caffeinated gum.

In the single-dose condition, participants chewed three pieces of caffeinated gum containing a total of 300 mg caffeine for 5 minutes. In the partial-dose condition, participants chewed one piece of caffeinated gum containing 100 mg caffeine at three different time points, with 30-minute intervals between doses. In the placebo condition, participants chewed caffeine-free gum for 5 minutes.

Each testing session included volleyball-specific activities and a 30-minute volleyball-specific skill game. Attack, block, and defense efficiency were assessed using video recordings and Data Volley software. Vertical jump height was measured before and after the volleyball-specific activity. Heart rate was recorded during the session, and rating of perceived exertion was assessed before and after the session. Participants were also asked to report side effects and to guess which condition they had received after each session.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

11

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Bornova
      • Izmir, Bornova, Tyrkiet (Türkiye), 35040
        • Ege University, Faculty of Sport Sciences

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen

Tager imod sunde frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Female volleyball players aged 18 to 35 years.
  • Apparently healthy.
  • Daily caffeine intake ≤300 mg.
  • Minimum of 5 years of regular volleyball training experience.
  • Training for at least 120 minutes at least 3 days per week.
  • Competing in national or international volleyball matches.
  • Provided written informed consent before participation.

Exclusion Criteria:

  • Serious injury or trauma within the past 6 months that could affect volleyball performance.
  • Illness or inability to continue the study protocol during the research period.
  • Development of side effects during caffeinated gum administration that prevented continuation.
  • Regular alcohol or drug use that could affect the study outcomes.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Placebo, Single-Dose Caffeine, Partial-Dose Caffeine Arm Type: Experimental
Participants received placebo gum in the first session, single-dose caffeinated gum in the second session, and partial-dose caffeinated gum in the third session. Sessions were separated by one week.
Participants chewed three pieces of caffeinated gum containing 100 mg caffeine per piece, providing a total dose of 300 mg caffeine. The gum was chewed for 5 minutes and then discarded.
Andre navne:
  • Caffeine gum
  • Caffeinated chewing gum
Participants received three separate pieces of caffeinated gum containing 100 mg caffeine per piece. One piece was chewed for 5 minutes at each administration time point, with doses given at 30-minute intervals, providing a total dose of 300 mg caffeine.
Andre navne:
  • Caffeine gum
  • Caffeinated chewing gum
Participants chewed caffeine-free placebo gum for 5 minutes. The placebo gum was selected to be similar in shape and color to the caffeinated gum.
Andre navne:
  • Caffeine-free gum
  • Placebo chewing gum
Eksperimentel: Placebo, Partial-Dose Caffeine, Single-Dose Caffeine
Participants received placebo gum in the first session, partial-dose caffeinated gum in the second session, and single-dose caffeinated gum in the third session. Sessions were separated by one week.
Participants chewed three pieces of caffeinated gum containing 100 mg caffeine per piece, providing a total dose of 300 mg caffeine. The gum was chewed for 5 minutes and then discarded.
Andre navne:
  • Caffeine gum
  • Caffeinated chewing gum
Participants received three separate pieces of caffeinated gum containing 100 mg caffeine per piece. One piece was chewed for 5 minutes at each administration time point, with doses given at 30-minute intervals, providing a total dose of 300 mg caffeine.
Andre navne:
  • Caffeine gum
  • Caffeinated chewing gum
Participants chewed caffeine-free placebo gum for 5 minutes. The placebo gum was selected to be similar in shape and color to the caffeinated gum.
Andre navne:
  • Caffeine-free gum
  • Placebo chewing gum
Eksperimentel: Single-Dose Caffeine, Placebo, Partial-Dose Caffeine
Participants received single-dose caffeinated gum in the first session, placebo gum in the second session, and partial-dose caffeinated gum in the third session. Sessions were separated by one week.
Participants chewed three pieces of caffeinated gum containing 100 mg caffeine per piece, providing a total dose of 300 mg caffeine. The gum was chewed for 5 minutes and then discarded.
Andre navne:
  • Caffeine gum
  • Caffeinated chewing gum
Participants received three separate pieces of caffeinated gum containing 100 mg caffeine per piece. One piece was chewed for 5 minutes at each administration time point, with doses given at 30-minute intervals, providing a total dose of 300 mg caffeine.
Andre navne:
  • Caffeine gum
  • Caffeinated chewing gum
Participants chewed caffeine-free placebo gum for 5 minutes. The placebo gum was selected to be similar in shape and color to the caffeinated gum.
Andre navne:
  • Caffeine-free gum
  • Placebo chewing gum
Eksperimentel: Single-Dose Caffeine, Partial-Dose Caffeine, Placebo
Participants received single-dose caffeinated gum in the first session, partial-dose caffeinated gum in the second session, and placebo gum in the third session. Sessions were separated by one week.
Participants chewed three pieces of caffeinated gum containing 100 mg caffeine per piece, providing a total dose of 300 mg caffeine. The gum was chewed for 5 minutes and then discarded.
Andre navne:
  • Caffeine gum
  • Caffeinated chewing gum
Participants received three separate pieces of caffeinated gum containing 100 mg caffeine per piece. One piece was chewed for 5 minutes at each administration time point, with doses given at 30-minute intervals, providing a total dose of 300 mg caffeine.
Andre navne:
  • Caffeine gum
  • Caffeinated chewing gum
Participants chewed caffeine-free placebo gum for 5 minutes. The placebo gum was selected to be similar in shape and color to the caffeinated gum.
Andre navne:
  • Caffeine-free gum
  • Placebo chewing gum
Eksperimentel: Partial-Dose Caffeine, Placebo, Single-Dose Caffeine
Participants received partial-dose caffeinated gum in the first session, placebo gum in the second session, and single-dose caffeinated gum in the third session. Sessions were separated by one week.
Participants chewed three pieces of caffeinated gum containing 100 mg caffeine per piece, providing a total dose of 300 mg caffeine. The gum was chewed for 5 minutes and then discarded.
Andre navne:
  • Caffeine gum
  • Caffeinated chewing gum
Participants received three separate pieces of caffeinated gum containing 100 mg caffeine per piece. One piece was chewed for 5 minutes at each administration time point, with doses given at 30-minute intervals, providing a total dose of 300 mg caffeine.
Andre navne:
  • Caffeine gum
  • Caffeinated chewing gum
Participants chewed caffeine-free placebo gum for 5 minutes. The placebo gum was selected to be similar in shape and color to the caffeinated gum.
Andre navne:
  • Caffeine-free gum
  • Placebo chewing gum
Eksperimentel: Partial-Dose Caffeine, Single-Dose Caffeine, Placebo
Participants received partial-dose caffeinated gum in the first session, single-dose caffeinated gum in the second session, and placebo gum in the third session. Sessions were separated by one week.
Participants chewed three pieces of caffeinated gum containing 100 mg caffeine per piece, providing a total dose of 300 mg caffeine. The gum was chewed for 5 minutes and then discarded.
Andre navne:
  • Caffeine gum
  • Caffeinated chewing gum
Participants received three separate pieces of caffeinated gum containing 100 mg caffeine per piece. One piece was chewed for 5 minutes at each administration time point, with doses given at 30-minute intervals, providing a total dose of 300 mg caffeine.
Andre navne:
  • Caffeine gum
  • Caffeinated chewing gum
Participants chewed caffeine-free placebo gum for 5 minutes. The placebo gum was selected to be similar in shape and color to the caffeinated gum.
Andre navne:
  • Caffeine-free gum
  • Placebo chewing gum

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Attack efficiency
Tidsramme: During the 30-minute volleyball-specific skill game in each experimental trial
Attack efficiency was assessed during a 30-minute volleyball-specific skill game using video recordings and Data Volley software. Values were expressed as percentages.
During the 30-minute volleyball-specific skill game in each experimental trial
Block efficiency
Tidsramme: During the 30-minute volleyball-specific skill game in each experimental trial
Block efficiency was assessed during a 30-minute volleyball-specific skill game using video recordings and Data Volley software. Values were expressed as percentages.
During the 30-minute volleyball-specific skill game in each experimental trial
Defense efficiency
Tidsramme: During the 30-minute volleyball-specific skill game in each experimental trial
Defense efficiency was assessed during a 30-minute volleyball-specific skill game using video recordings and Data Volley software. Values were expressed as percentages.
During the 30-minute volleyball-specific skill game in each experimental trial

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in vertical jump height
Tidsramme: From immediately before to immediately after each experimental trial
Vertical jump height was measured before and after each experimental testing session using a photoelectric cell system. Values were expressed in centimeters.
From immediately before to immediately after each experimental trial
Heart rate
Tidsramme: Continuously during each experimental trial
Heart rate was recorded during each experimental testing session using a telemetric heart rate monitoring system. Values were expressed as beats per minute.
Continuously during each experimental trial
Change in rating of perceived exertion
Tidsramme: From immediately before to immediately after each experimental trial
Rating of perceived exertion was assessed before and after each experimental testing session using a 0-10 Borg scale.
From immediately before to immediately after each experimental trial

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Side effects
Tidsramme: Immediately after each experimental trial
Participants were asked after each experimental testing session whether they experienced any side effects or discomfort related to the gum intervention. Reported responses were recorded descriptively.
Immediately after each experimental trial

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

5. august 2025

Primær færdiggørelse (Faktiske)

23. april 2026

Studieafslutning (Faktiske)

23. april 2026

Datoer for studieregistrering

Først indsendt

11. maj 2026

Først indsendt, der opfyldte QC-kriterier

15. maj 2026

Først opslået (Faktiske)

19. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. maj 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • EGE-25-9.1T-28

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual participant data will not be shared because the dataset contains participant-level performance and physiological data from a small group of elite female volleyball players, which may increase the risk of participant identification.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner